Sanofi is investing €170m to expand its vaccine manufacturing site in Val de Reuil, France, which produces 900 million vaccine doses worldwide each year.
British researchers have identified interleukin 36 (IL-36) as a druggable proinflammatory driver of psoriasis. Because of its very targeted effects of antibodies directed against the cytokine they want to start clinical tests in man.
German-Israeli Neurim Pharmaceuticals announced top line efficacy results of its insomnia drug PedPRM in children with autism spectrum disorders (ASD).
French cancer drug encapsulation specialist Erytech Pharma SA wants to raise US$100m (€85m) in an IPO at NASDAQ and a subsequent private placement outside Northern America to finance pivotal trials of eryaspase in ALL and pancreatic cancer.
As first gene therapy ever, AMT-130 has been granted FDA Orphan Drug status in Huntingtons Disease.
Microsart ® @media Advanced System for Touch-free Membrane Transfer.
Promethera Biosciences and Shibuya collaborate to establish a breakthrough cell therapy manufacturing platform.
Cancer immunotherapy specialist Immatics Biotechnologies GmbH (Tuebingen, Germany) raised US$58m in a Series E financing round led by German investors dievini Hopp BioTech Holding and AT Impf as well as Wellington Partners and new investor Amgen.
Late-stage pharmaceuticals financing and co-development specialist Avillion LLP has named Kathryn J. Gregory Chief Business Officer.
Scotch cancer corp NuCana plc was up 3% (to US$18.61) after closing an initial public offering on Friday led by Citigroup, Jefferies and Cowen and co-managed by William Blair.